{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:31:12Z","timestamp":1771273872795,"version":"3.50.1"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Epidemiological data clearly indicate a link between hepatitis C virus (HCV) and altered glucose homeostasis.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> To evaluate the response of treatment with direct antiviral agents (DAAs) on metabolic variables of patients with hepatitis C.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Observational, cross-sectional study in a sample of patients with hepatitis C starting therapy with DAAs followed on the hepatology division of Federal University of Rio de Janeiro State. Data were collected in two stages: before the start of therapy and between 12 and 52 weeks after obtaining the sustained virological response.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> In the baseline assessment of the 97 patients selected, 19.3% were obese, 38.6% were overweight, 50% were hypertensive, 43.8% were pre-diabetic, 12.5% were diabetic, 31.2% were dyslipidemic, and 21.8% had metabolic syndrome. There was an increase in total cholesterol and LDL levels (<jats:italic>p<\/jats:italic> &amp;lt; 0.001), and a non-significant reduction in blood glucose, glycated hemoglobin, insulin, and HOMA-IR levels after treatment. In the post-treatment, there was a reduction in fibrosis (<jats:italic>p<\/jats:italic> = 0.016), with a reduction in the levels of GGT, AST, and ALT (all with <jats:italic>p<\/jats:italic> &amp;lt; 0.001), as well as in the FIB4 and APRI scores (both with <jats:italic>p<\/jats:italic> &amp;lt; 0.001) and in the degree of fibrosis evaluated by elastography represented in kPa (<jats:italic>p<\/jats:italic> = 0.006). The blood glucose level was higher in patients with steatosis (<jats:italic>p<\/jats:italic> = 0.039) after treatment. There was a positive pre-treatment correlation between the degree of fibrosis (kPa) and FIB4 (<jats:italic>r<\/jats:italic> = 0.319, <jats:italic>p<\/jats:italic> = 0.004), APRI (<jats:italic>r<\/jats:italic> = 0.287, <jats:italic>p<\/jats:italic> = 0.010), and the NAFLD score (<jats:italic>r<\/jats:italic> = 0.275, <jats:italic>p<\/jats:italic> = 0.016).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Patients with hepatitis C had a high prevalence of metabolic disturbance in the pre-treatment phase, but the therapy did not show beneficial effects, especially on glucose metabolism.<\/jats:p>","DOI":"10.3389\/fmed.2021.631600","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T05:07:14Z","timestamp":1622437634000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents"],"prefix":"10.3389","volume":"8","author":[{"given":"Sergio","family":"Estefan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Eduardo","family":"Brand\u00e3o-Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cintia Marques","family":"dos Santos Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo Cosme Klein","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia Helena S.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/cld.783","article-title":"Epidemiology of hepatitis C","volume":"12","author":"Jafri","year":"2018","journal-title":"Clin Liver Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(19)32320-7","article-title":"Hepatitis C","volume":"394","author":"Spearman","year":"2019","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/apt.13633","article-title":"Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis","volume":"43","author":"Majumdar","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.4254\/wjh.v7.i24.2543","article-title":"Era of direct acting antivirals in chronic hepatitis C: who will benefit?","volume":"7","author":"Fung","year":"2015","journal-title":"World J Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/hep.20750","article-title":"Steatosis: co-factor in other liver diseases","volume":"42","author":"Powell","year":"2005","journal-title":"Hepatology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/apt.12234","article-title":"Associations of chronic hepatitis C with metabolic and cardiac outcomes","volume":"37","author":"Younossi","year":"2013","journal-title":"Aliment Pharmacol Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1478-3231.2009.02185.x","article-title":"Hepatitis C and diabetes: one treatment for two diseases?","volume":"30","author":"Pattullo","year":"2010","journal-title":"Liver Int."},{"key":"B9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1053\/jhep.2003.50291","article-title":"Hepatitis C virus infection and incident type 2 diabetes","volume":"38","author":"Mehta","year":"2003","journal-title":"Hepatology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/jmv.24954","article-title":"Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents","volume":"90","author":"Ciancio","year":"2018","journal-title":"J Med Virol."},{"key":"B11","volume-title":"Conduta Terap\u00eautica no diabetes tipo 2: Algoritmo SBD 2019","year":"2019"},{"key":"B12","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/dc19-S002","article-title":"Classification and diagnosis of diabetes: standards of medical care in diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"B13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1161\/CIR.0000000000000678","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabetes Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","author":"Cast\u00e9ra","year":"2005","journal-title":"Gastroenterology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.1478-3231.2012.02820.x","article-title":"Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography","volume":"32","author":"de","year":"2012","journal-title":"Liver Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.bjid.2019.04.010","article-title":"Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach","volume":"23","author":"Benzaken","year":"2019","journal-title":"Braz J Infect Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.15403\/jgld.2014.1121.273.daa","article-title":"Impact of direct acting antiviral (DAA) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C","volume":"27","author":"Weidner","year":"2018","journal-title":"J Gastrointest Liver Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/jvh.12879","article-title":"Cirrhosis, high age high body mass index are risk factors for persisting advanced fibrosis after sustained virological response in chronic hepatitis C","volume":"25","author":"Hedenstierna","year":"2018","journal-title":"J Viral Hepat."},{"key":"B25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0168-8278(03)00479-3","article-title":"Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States","volume":"40","author":"Hu","year":"2004","journal-title":"J Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"708","DOI":"10.5152\/tjg.2019.18514","article-title":"A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens","volume":"30","author":"El Kassas","year":"2019","journal-title":"Turk J Gastroenterol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"68","author":"Ioannou","year":"2018","journal-title":"J Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1007\/s11606-020-06227-w","article-title":"Excess weight gain after cure of hepatitis C infection with direct-acting antivirals","volume":"35","author":"Do","year":"2020","journal-title":"J Gen Intern Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000493945","article-title":"Prevalence of type 2 diabetes mellitus among hepatitis C virus-infected patients: a systematic review and meta-analysis","volume":"21","author":"Ambachew","year":"2018","journal-title":"Int J Diabetes Metab."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1038\/s41598-020-58786-x","article-title":"Hepatitis C virus clearance with glucose improvement and factors affecting the glucose control in chronic hepatitis c patients","volume":"10","author":"Yuan","year":"2020","journal-title":"Sci Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1111\/j.1572-0241.2008.01996.x","article-title":"Reappraisal of the characteristics of glucose abnormalities in patients with chronic hepatitis C infection","volume":"103","author":"Huang","year":"2008","journal-title":"Am J Gastroenterol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"12903","DOI":"10.1128\/JVI.01418-12","article-title":"Hepatitis C virus infection suppresses GLUT2 gene expression via down regulation of hepatocyte nuclear factor 1\u03b1","volume":"86","author":"Matsui","year":"2012","journal-title":"J Virol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"462.e461","DOI":"10.1016\/j.cmi.2015.12.030","article-title":"Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents","volume":"22","author":"Pavone","year":"2016","journal-title":"Clin Microbiol Infect."},{"key":"B34","doi-asserted-by":"publisher","first-page":"6438753","DOI":"10.1155\/2020\/6438753","article-title":"Impact of treatment with direct acting antiviral drugs on glycemic control in patients with hepatitis C and diabetes mellitus","volume":"2020","author":"Mada","year":"2020","journal-title":"Int J Hepatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4093\/dmj.2017.41.4.316","article-title":"Factors associated with improved glycemic control by direct-acting antiviral agent treatment in Egyptian type 2 diabetes mellitus patients with chronic hepatitis C genotype 4","volume":"41","author":"Dawood","year":"2017","journal-title":"Diabetes Metab J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2337\/dc17-0485","article-title":"Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus","volume":"40","author":"Hum","year":"2017","journal-title":"Diabetes Care."},{"key":"B37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/infdis\/jix517","article-title":"No improvement in hemoglobin A1c following hepatitis C viral clearance in patients with and without HIV","volume":"217","author":"Chaudhury","year":"2018","journal-title":"J Infect Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/liv.13669","article-title":"Hepatitis C virus eradication by direct antiviral agents improves glucose tolerance and reduces post-load insulin resistance in nondiabetic patients with genotype 1","volume":"38","author":"Salomone","year":"2018","journal-title":"Liver Int."},{"key":"B39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.5604\/16652681.1231581","article-title":"Effect of treatment with direct acting antiviral on glycemic control in patients with diabetes mellitus and chronic hepatitis C","volume":"16","author":"Stine","year":"2017","journal-title":"Ann Hepatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1111\/dom.14168","article-title":"Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: a prospective study","volume":"22","author":"Adinolfi","year":"2020","journal-title":"Diabetes Obes Metab."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/liv.14031","article-title":"Sustained virological response does not improve long-term glycaemic control in patients with type 2 diabetes and chronic hepatitis C","volume":"39","author":"Li","year":"2016","journal-title":"Liver Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/hep.27424","article-title":"Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1\u2013 infected patients","volume":"61","author":"Meissner","year":"2015","journal-title":"Hepatology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"21313","DOI":"10.18632\/oncotarget.25092","article-title":"The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C","volume":"9","author":"Batsaikhan","year":"2018","journal-title":"Oncotarget"},{"key":"B44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3851\/IMP3094","article-title":"Short communication Effect of antiviral therapy for HCV on lipid levels","volume":"22","author":"Mauss","year":"2017","journal-title":"Antiviral Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e0163644","DOI":"10.1371\/journal.pone.0163644","article-title":"Rapid increase in serum low-density lipoprotein cholesterol concentration during hepatitis C interferon-free treatment","volume":"11","author":"Hashimoto","year":"2016","journal-title":"PLoS ONE"},{"key":"B46","doi-asserted-by":"publisher","first-page":"7845","DOI":"10.1038\/s41598-018-26293-9","article-title":"Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter","volume":"8","author":"Shimizu","year":"2018","journal-title":"Sci Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/MEG.0000000000001316","article-title":"Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients","volume":"31","author":"Lybeck","year":"2019","journal-title":"Euro J Gastroenterol Hepatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1097\/MEG.0000000000001106","article-title":"Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response","volume":"30","author":"Kobayashi","year":"2018","journal-title":"Euro J Gastroenterol Hepatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12876-019-0973-5","article-title":"Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents","volume":"19","author":"Hsu","year":"2019","journal-title":"BMC Gastroenterol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/jvh.12224","article-title":"The validity of serum markers for fibrosis staging in chronic hepatitis B and C","volume":"21","author":"Li","year":"2014","journal-title":"J Viral Hepat."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.3748\/wjg.v24.i11.1269","article-title":"Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals","volume":"24","author":"Noureddin","year":"2018","journal-title":"World J Gastroenterol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"258","DOI":"10.14218\/JCTH.2018.00014","article-title":"Hepatitis C virus clearance by direct-acting antiviral results in rapid resolution of hepatocytic injury as indicated by both alanine aminotransferase and aspartate aminotransferase normalization","volume":"6","author":"Huynh","year":"2018","journal-title":"J Clin Transl Hepatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e0171755","DOI":"10.1371\/journal.pone.0171755","article-title":"Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response","volume":"12","author":"Welsch","year":"2017","journal-title":"PLoS ONE"},{"key":"B54","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1590\/s0004-2803.201800000-74","article-title":"Hepatitis C in the Brazilian public health care system: burden of disease","volume":"55","author":"Castelo","year":"2018","journal-title":"Arqu Gastroenterol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e16254","DOI":"10.1097\/MD.0000000000016254","article-title":"Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance","volume":"98","author":"Loo","year":"2019","journal-title":"Medicine."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.631600\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T05:07:17Z","timestamp":1622437637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.631600\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":55,"alternative-id":["10.3389\/fmed.2021.631600"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.631600","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,31]]},"article-number":"631600"}}